List of Stem Cells Companies in Australia - 9

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.

Cartherics works to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Inventia Life Science is making advanced cell models easy for high impact discovery. The company's strong foundation of fundamental research has led to the development of proprietary solutions to generate high-quality advanced cell models that are reproducible and highly consistent. Built by scientists for scientists, our intuitive solutions integrate seamlessly with existing workflows, whereas our wide range of biofunctional synthetic matrices and application-driven models make your desired assays possible.

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.

Ozgene offers the full spectrum of capabilities to design, generate, breed & phenotype your mouse models. It was not that long ago that a mouse was just a mouse but, for the team at Ozgene, a mouse represents a way to advance humanity. Started 15 years ago, today, Ozgene is one of the leading companies providing genetically customised mice for researchers around the world. With best in industry timelines using their goGermline embryos other services include knock-in, knockout, humanized and transgenic mouse models, breeding and husbandry, validation and phenotyping and Geneoz VMS. Ozgene has developed a new goGermline approach, which is a revolutionary new technology to generate knockout and knock-in mice fast and efficiently, while improving animal welfare. Ozgene is now able to complete projects in less than 6 months. Whilst, Ozgene is an Australian company, 80% of their clients are located overseas and shipments leave the Ozgene facility almost daily for laboratories, small academic institutions, research institutes, biotechnology companies and multinational pharmaceutical companies in the US, Europe, Asia, South America and New Zealand. CEO and Co-founder, Dr Frank Koentgen, and the Ozgene team have over 20 years of experience in the generation of genetically modified mice. It begins even before Ozgene was born, when Dr Koentgen generated the first knockout mouse from the C57BL/6 mouse strain in 1993. Work has been published in scientific journals such as Cell, Nature, Science, Immunity, PNAS and Nature Medicine.

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

S2N’s vision is a world where neuronal loss no longer means loss. Our regenerative medicine technology starts with the human hair follicle and ends with production of millions of pure neurons, all gene modification free. We aim to transform health, science and society.

Tessara Therapeutics Pty Ltd is a regenerative medicine company developing RealBrain® technology to break therapeutic barriers in the biopharmaceutical industry. RealBrain® technology is based on human mimetic 3D neural micro-tissues designed to have high physiological relevance, manufactured at industrial scale for unprecedented reproducibility. Priority applications include a high-throughput drug screening platform that includes a range of models of healthy and diseased brain tissue, and a regenerative medicine platform to develop next generation safe and efficacious tissue therapies for significant unmet neurological medical needs.